, a bio/informatics shared resource is still "open for business" - Visit the CDS website


  1. Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. Schafer JM, Lehmann BD, Gonzalez-Ericsson PI, Marshall CB, Beeler JS, Redman LN, Jin H, Sanchez V, Stubbs MC, Scherle P, Johnson KN, Sheng Q, Roland JT, Bauer JA, Shyr Y, Chakravarthy B, Mobley BC, Hiebert SW, Balko JM, Sanders ME, Liu PCC, Pietenpol JA (2020) Sci Transl Med 12(534)
    › Primary publication · 32161105 (PubMed)
  2. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR Metastatic Triple-Negative Breast Cancer. Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, Shyr Y, Arteaga CL, Wolff AC, Pietenpol JA, Translational Breast Cancer Research Consortium (2019) Clin Cancer Res
    › Primary publication · 31822498 (PubMed)
  3. p73 regulates epidermal wound healing and induced keratinocyte programming. Beeler JS, Marshall CB, Gonzalez-Ericsson PI, Shaver TM, Santos Guasch GL, Lea ST, Johnson KN, Jin H, Venters BJ, Sanders ME, Pietenpol JA (2019) PLoS One 14(6): e0218458
    › Primary publication · 31216312 (PubMed) · PMC6583996 (PubMed Central)
  4. Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations. Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sánchez V, Shyr Y, Sanders ME, Pietenpol JA (2019) Mol Cancer Res 17(9): 1842-1853
    › Primary publication · 31186280 (PubMed) · PMC6726520 (PubMed Central)
  5. p73 regulates ependymal planar cell polarity by modulating actin and microtubule cytoskeleton. Fuertes-Alvarez S, Maeso-Alonso L, Villoch-Fernandez J, Wildung M, Martin-Lopez M, Marshall C, Villena-Cortes AJ, Diez-Prieto I, Pietenpol JA, Tissir F, Lizé M, Marques MM, Marin MC (2018) Cell Death Dis 9(12): 1183
    › Primary publication · 30518789 (PubMed) · PMC6281643 (PubMed Central)
  6. p73 Is Required for pIgR Expression in the Respiratory Epithelium. Richmond BW, Du RH, Marshall C, Pietenpol J, Polosukhin VV, Blackwell TS (2018) Ann Am Thorac Soc 15(Supplement_4): S290
    › Primary publication · 30759000 (PubMed) · PMC6322007 (PubMed Central)
  7. p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. Santos Guasch GL, Beeler JS, Marshall CB, Shaver TM, Sheng Q, Johnson KN, Boyd KL, Venters BJ, Cook RS, Pietenpol JA (2018) iScience : 236-249
    › Primary publication · 30340069 (PubMed) · PMC6197761 (PubMed Central)
  8. Corrigendum to "Comparative Study of Exome Copy Number Variation Estimation Tools Using Array Comparative Genomic Hybridization as Control". Guo Y, Sheng Q, Samuels DC, Lehmann B, Bauer JA, Pietenpol J, Shyr Y (2017) Biomed Res Int : 7409598
    › Primary publication · 28804721 (PubMed) · PMC5540237 (PubMed Central)
  9. Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. Jovanović B, Sheng Q, Seitz RS, Lawrence KD, Morris SW, Thomas LR, Hout DR, Schweitzer BL, Guo Y, Pietenpol JA, Lehmann BD (2017) BMC Cancer 17(1): 241
    › Primary publication · 28376728 (PubMed) · PMC5379658 (PubMed Central)
  10. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA (2017) Clin Cancer Res 23(15): 4035-4045
    › Primary publication · 28270498 (PubMed) · PMC5540799 (PubMed Central)